Newswise — Uppsala, Sweden – July 26, 2025 – Rarity Bioscience is proud to announce its selection as a finalist for the prestigious Disruptive Technology Award at the Association for Diagnostics & Laboratory Medicine (ADLM) 2025 Annual Meeting, in recognition of its groundbreaking superRCA® technology for ultra-sensitive mutation detection.
Designed to address the demanding sensitivity needs for precision medicine, superRCA® (super Rolling Circle Amplification) radically advances precision, scalability and accessibility of mutation detection. By combining molecular specificity with analysis using existing flow cytometry instruments, the technology enables decentralized mutation detection at levels previously considered unattainable.
“Being selected as a finalist for the Disruptive Technology Award at ADLM is a powerful endorsement of our vision to democratic mutation detection,” said Linus Bosaeus, CEO of Rarity Bioscience. “superRCA represents a leap forward in molecular diagnostics, and we’re honored to be recognized among the innovators shaping the future of patient care.”
The ADLM Annual Meeting is one of the world’s largest gatherings of laboratory medicine professionals, showcasing cutting-edge science, emerging technologies, and the most impactful diagnostic tools of tomorrow.
Rarity Bioscience will present its technology during the Disruptive Technology Award session at ADLM 2025, offering attendees to learn more about the superRCA platform and its transformative potential. In addition to the presentation, Rarity will be present throughout the conference with a dedicated booth and on-site team, available for questions and technical discussions.
About: Rarity Bioscience is a Swedish life science company dedicated to advancing precision medicine through innovative molecular technologies. With superRCA at its core, the company enables sensitive, reliable, and scalable mutation detection for liquid biopsies and minimal residual disease research applications across cancers.
